<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37511837</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-1729</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>28</Day></PubDate></JournalIssue><Title>Life (Basel, Switzerland)</Title><ISOAbbreviation>Life (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Renin-Angiotensin System in COVID-19: Can Long COVID Be Predicted?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1462</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/life13071462</ELocationID><Abstract><AbstractText>(1) Background: Co-morbidities such as hypertension and cardiovascular disease are major risk factors for severe COVID-19. The renin-angiotensin system (RAS) is critically involved in their pathophysiology and is counter-balanced by both angiotensin-converting enzyme 2 (ACE2), the functional receptor of SARS-CoV-2, and the kallikrein-kinin system (KKS). Considerable research interest with respect to COVID-19 treatment is currently being directed towards the components of these systems. In earlier studies, we noticed significantly reduced carboxypeptidase N (CPN, KKS member) activity and excessive angiotensin-converting enzyme (ACE, RAS member) activity in the sera of both hospitalized COVID-19 patients and a subgroup of convalescent patients. The data had been obtained using labeled bradykinin (BK) as a reporter peptide, which is a target of both CPN and ACE. The data were supplemented with mass-spectrometry-based serum proteomic analysis. Here, we hypothesize that the degree of BK serum degradation could be indicative of Long COVID. (2) Review and Discussion: The recent literature is briefly reviewed. The fact that the levels of the BK serum degradation products did not reach normal concentrations in almost half of the patients during convalescences could have been partially due to a dysregulated RAS. (3) Conclusions: Standard tests for routine patient care in Long COVID come often back normal. We suggest that the measurement of selected members of the RAS such as ACE and angiotensin II or the use of our BK degradation assay could identify Long COVID candidates. Clinical studies are required to test this hypothesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>K&#xf6;nig</LastName><ForeName>Simone</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0672-7246</Identifier><AffiliationInfo><Affiliation>IZKF Core Unit Proteomics, University of M&#xfc;nster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vollenberg</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tepasse</LastName><ForeName>Phil-Robin</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0002-2757-4755</Identifier><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Life (Basel)</MedlineTA><NlmUniqueID>101580444</NlmUniqueID><ISSNLinking>2075-1729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE</Keyword><Keyword MajorTopicYN="N">ACE inhibitors</Keyword><Keyword MajorTopicYN="N">ACE2</Keyword><Keyword MajorTopicYN="N">CPN</Keyword><Keyword MajorTopicYN="N">RAS</Keyword><Keyword MajorTopicYN="N">angiotensin receptor blockers</Keyword><Keyword MajorTopicYN="N">antihypertensive</Keyword><Keyword MajorTopicYN="N">bradykinin</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">mass spectrometry</Keyword><Keyword MajorTopicYN="N">neuropeptide reporter assay</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37511837</ArticleId><ArticleId IdType="pmc">PMC10381802</ArticleId><ArticleId IdType="doi">10.3390/life13071462</ArticleId><ArticleId IdType="pii">life13071462</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angeli F., Zappa M., Reboldi G., Gentile G., Trapasso M., Spanevello A., Verdecchia P. The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure. Eur. J. Intern. Med. 2023;109:12&#x2013;21. doi: 10.1016/j.ejim.2022.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2022.12.004</ArticleId><ArticleId IdType="pmc">PMC9744686</ArticleId><ArticleId IdType="pubmed">36528504</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz Ocaranza M., Riquelme J.A., Garc&#xed;a L., Jalil J.E., Chiong M., Santos R.A.S., Lavandero S. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat. Rev. Cardiol. 2020;17:116&#x2013;129. doi: 10.1038/s41569-019-0244-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-019-0244-8</ArticleId><ArticleId IdType="pmc">PMC7097090</ArticleId><ArticleId IdType="pubmed">31427727</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Peng J., Wang T., Wen J., Chen S., Huang Y., Zhang Y. Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic. Biochem. Pharmacol. 2023;208:115370. doi: 10.1016/j.bcp.2022.115370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2022.115370</ArticleId><ArticleId IdType="pmc">PMC9721294</ArticleId><ArticleId IdType="pubmed">36481346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer M., K&#xf6;nig S. A vote for robustness: Monitoring serum enzyme activity by thin-layer chromatography of dabsylated bradykinin products. J. Pharmaceut. Biomed. Anal. 2017;143:199&#x2013;203. doi: 10.1016/j.jpba.2017.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2017.06.007</ArticleId><ArticleId IdType="pubmed">28605681</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepasse P.-R., Vollenberg R., Steinebrey N., K&#xf6;nig S. High angiotensin-converting enzyme and low carboxypeptidase N serum activity correlate with disease severity in COVID-19 patients. J. Pers. Med. 2022;12:406. doi: 10.3390/jpm12030406.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12030406</ArticleId><ArticleId IdType="pmc">PMC8949860</ArticleId><ArticleId IdType="pubmed">35330406</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepasse P.-R., Vollenberg R., Steinebrey N., K&#xf6;nig S. The dysregulation of the renin-angiotensin-system in COVID-19 studied by serum proteomics: Angiotensinogen increases with disease severity. Molecules. 2022;27:2495. doi: 10.3390/molecules27082495.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27082495</ArticleId><ArticleId IdType="pmc">PMC9025241</ArticleId><ArticleId IdType="pubmed">35458690</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabassum A., Iqbal M.S., Sultan S., Alhuthali R.A., Alshubaili D.I., Sayyam R.S., Abyad L.M., Qasem A.H., Arbaeen A.F. Dysregulated bradykinin: Mystery in the pathogenesis of COVID-19. Mediat. Inflamm. 2022;2022:7423537. doi: 10.1155/2022/7423537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/7423537</ArticleId><ArticleId IdType="pmc">PMC8826266</ArticleId><ArticleId IdType="pubmed">35153624</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho P.R., Sirois P., Fernandes P.D. The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. Peptides. 2021;135:170428. doi: 10.1016/j.peptides.2020.170428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2020.170428</ArticleId><ArticleId IdType="pmc">PMC7553876</ArticleId><ArticleId IdType="pubmed">33065209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawal I.O., Kgatle M.M., Mokoala K., Farate A., Sathekge M.M. Cardiovascular disturbances in COVID-19: An updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2. BMC Cardiovasc. Disord. 2022;22:93. doi: 10.1186/s12872-022-02534-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-022-02534-8</ArticleId><ArticleId IdType="pmc">PMC8905284</ArticleId><ArticleId IdType="pubmed">35264107</ArticleId></ArticleIdList></Reference><Reference><Citation>Schieffer E., Schieffer B. The race for ACE: Targeting angiotensin-converting enzymes (ACE) in SARS-CoV-2 infection. J. Renin-Angiotensin-Aldosterone Syst. JRAAS. 2022;2022:2549063. doi: 10.1155/2022/2549063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/2549063</ArticleId><ArticleId IdType="pmc">PMC9166989</ArticleId><ArticleId IdType="pubmed">35685188</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews K.W., Mueller-Ortiz S.L., Wetsel R.A. Carboxypeptidase N: A pleiotropic regulator of inflammation. Mol. Immunol. 2004;40:785&#x2013;793. doi: 10.1016/j.molimm.2003.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2003.10.002</ArticleId><ArticleId IdType="pubmed">14687935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrenak J., Paulis L., Simko F. Angiotensin A/alamandine/MrgD axis: Another clue to understanding cardiovascular pathophysiology. Int. J. Mol. Sci. 2016;17:1098. doi: 10.3390/ijms17071098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17071098</ArticleId><ArticleId IdType="pmc">PMC4964474</ArticleId><ArticleId IdType="pubmed">27447621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucena J.F., Alegre F., Martinez-Urbistondo D., Landecho M.F., Huerta A., Garcia-Mouriz A., Garcia N., Quiroga J. Performance of SAPS II and SAPS 3 in intermediate care. PLoS ONE. 2013;8:e77229. doi: 10.1371/journal.pone.0077229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0077229</ArticleId><ArticleId IdType="pmc">PMC3793951</ArticleId><ArticleId IdType="pubmed">24130860</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbraith M.D., Kinning K.T., Sullivan K.D., Baxter R., Araya P., Jordan K.R., Russell S., Smith K.P., Granrath R.E., Shaw J., et al. Seroconversion stages COVID19 into distinct pathophysiological states. eLife. 2021;10:e65508. doi: 10.7554/eLife.65508.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.65508</ArticleId><ArticleId IdType="pmc">PMC7963480</ArticleId><ArticleId IdType="pubmed">33724185</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., Boon A.C.M., Michelson A.P., Foraker R.E., Zhan M., Payne P.R.O. Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19. Sci. Rep. 2022;12:9462. doi: 10.1038/s41598-022-13585-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13585-4</ArticleId><ArticleId IdType="pmc">PMC9175532</ArticleId><ArticleId IdType="pubmed">35676404</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning Q., Wu D., Wang X., Xi D., Chen T., Chen G., Wang H., Lu H., Wang M., Zhu L., et al. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduct. Target. Ther. 2022;7:57. doi: 10.1038/s41392-022-00907-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00907-1</ArticleId><ArticleId IdType="pmc">PMC8863906</ArticleId><ArticleId IdType="pubmed">35197452</ArticleId></ArticleIdList></Reference><Reference><Citation>Armato J., DeFronzo R.A., Chiu S.T., Rider D., Ruby R. Are angiotensin-converting enzyme inhibitors/angiotensin receptor blockers associated with reduced severe acute respiratory syndrome coronavirus 2 infections and improved outcomes, and does race matter? Diabetes Obes. Metab. 2022;24:2465&#x2013;2468. doi: 10.1111/dom.14835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14835</ArticleId><ArticleId IdType="pmc">PMC9539006</ArticleId><ArticleId IdType="pubmed">35971756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba K., Imai Y., Rao S., Gao H., Guo F., Guan B. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005;11:875&#x2013;879. doi: 10.1038/nm1267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1267</ArticleId><ArticleId IdType="pmc">PMC7095783</ArticleId><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold R.G. COVID-19&#x2014;Does this disease kill due to imbalance of the renin angiotensin system (RAS) caused by genetic and gender differences in the response to viral ACE2 attack? Heart Lung Circ. 2020;29:964&#x2013;972. doi: 10.1016/j.hlc.2020.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2020.05.004</ArticleId><ArticleId IdType="pmc">PMC7247492</ArticleId><ArticleId IdType="pubmed">32564908</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas M., Kali M.S.K. Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: Meta-analysis. Sci. Rep. 2021;11:5012. doi: 10.1038/s41598-021-84678-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84678-9</ArticleId><ArticleId IdType="pmc">PMC7930241</ArticleId><ArticleId IdType="pubmed">33658619</ArticleId></ArticleIdList></Reference><Reference><Citation>Skarstein Kolberg E. ACE2, COVID19 and serum ACE as a possible biomarker to predict severity of disease. J. Clin. Virol. 2020;126:104350. doi: 10.1016/j.jcv.2020.104350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104350</ArticleId><ArticleId IdType="pmc">PMC7129721</ArticleId><ArticleId IdType="pubmed">32283335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kai H., Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors&#x2014;Lessons from available evidence and insights into COVID-19. Hypertens. Res. 2020;43:648&#x2013;654. doi: 10.1038/s41440-020-0455-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41440-020-0455-8</ArticleId><ArticleId IdType="pmc">PMC7184165</ArticleId><ArticleId IdType="pubmed">32341442</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V., Corballis N., Vassiliou V.S. Renin-angiotensin-aldosterone inhibitors and COVID-19 infection. Curr. Hypertens. Rep. 2022;24:425&#x2013;433. doi: 10.1007/s11906-022-01207-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-022-01207-3</ArticleId><ArticleId IdType="pmc">PMC9206216</ArticleId><ArticleId IdType="pubmed">35716247</ArticleId></ArticleIdList></Reference><Reference><Citation>Sel&#xe7;uk M., &#xc7;&#x131;nar T., Keskin M., &#xc7;i&#xe7;ek V., K&#x131;l&#x131;&#xe7; &#x15e;., Kenan B., Do&#x11f;an S., Asal S., G&#xfc;nay N., Y&#x131;ld&#x131;r&#x131;m E., et al. Is the use of ACE inb/ARBs associated with higher in-hospital mortality in COVID-19 pneumonia patients? Clin. Exp. Hypertens. 2020;42:738&#x2013;742. doi: 10.1080/10641963.2020.1783549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10641963.2020.1783549</ArticleId><ArticleId IdType="pubmed">32569491</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta N., Kalra A., Nowacki A.S., Anjewierden S., Han Z., Bhat P., Carmona-Rubio A.E., Jacob M., Procop G.W., Harrington S., et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5:1020&#x2013;1026. doi: 10.1001/jamacardio.2020.1855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1855</ArticleId><ArticleId IdType="pmc">PMC7201375</ArticleId><ArticleId IdType="pubmed">32936273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra M.R., Desai S.S., Kuy S.R., Henry T.D., Patel A.N. Cardiovascular disease, drug therapy, and mortality in COVID-19. N. Engl. J. Med. 2020;382:e102. doi: 10.1056/NEJMoa2007621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007621</ArticleId><ArticleId IdType="pmc">PMC7206931</ArticleId><ArticleId IdType="pubmed">32356626</ArticleId></ArticleIdList></Reference><Reference><Citation>Duvvuri V.R., Baumgartner A., Molani S., Hernandez P.V., Yuan D., Roper R.T., Matos W.F., Robinson M., Su Y., Subramanian N., et al. Angiotensin-converting enzyme (ACE) inhibitors may moderate COVID-19 hyperinflammatory response: An observational study with deep immunophenotyping. Health Data Sci. 2022;2022:0002. doi: 10.34133/hds.0002.</Citation><ArticleIdList><ArticleId IdType="doi">10.34133/hds.0002</ArticleId><ArticleId IdType="pmc">PMC9934012</ArticleId><ArticleId IdType="pubmed">36817759</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K., White N., Fanning J.P., Obonyo N., Yamashita M.H., Appadurai V., Ciullo A., May M., Worku E.T., Helms L., et al. Impact of renin&#x2013;angiotensin&#x2013;aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: A prospective cohort study. BMC Cardiovasc. Disord. 2022;22:123. doi: 10.1186/s12872-022-02565-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-022-02565-1</ArticleId><ArticleId IdType="pmc">PMC8942148</ArticleId><ArticleId IdType="pubmed">35321649</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang N.X., Yuan Q., Fang F., Yan B.P., Sanderson J.E. Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19. PLoS ONE. 2023;18:e0280280. doi: 10.1371/journal.pone.0280280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0280280</ArticleId><ArticleId IdType="pmc">PMC9836310</ArticleId><ArticleId IdType="pubmed">36634085</ArticleId></ArticleIdList></Reference><Reference><Citation>Loader J., Taylor F.C., Lampa E., Sundstr&#xf6;m J. Renin-angiotensin aldosterone system inhibitors and COVID-19: A systematic review and meta-analysis revealing critical bias across a body of observational research. J. Am. Heart Assoc. 2022;11:e025289. doi: 10.1161/JAHA.122.025289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.122.025289</ArticleId><ArticleId IdType="pmc">PMC9238740</ArticleId><ArticleId IdType="pubmed">35624081</ArticleId></ArticleIdList></Reference><Reference><Citation>Trump S., Lukassen S., Anker M.S., Chua R.L., Liebig J., Th&#xfc;rmann L., Corman V.M., Binder M., Loske J., Klasa C., et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat. Biotechnol. 2021;39:705&#x2013;716. doi: 10.1038/s41587-020-00796-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-00796-1</ArticleId><ArticleId IdType="pubmed">33361824</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H.J., Li Y., Wang D.Y., Yuan H.T. ARB might be superior to ACEI for treatment of hypertensive COVID-19 patients. J. Cell. Mol. Med. 2021;25:11031&#x2013;11034. doi: 10.1111/jcmm.17051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.17051</ArticleId><ArticleId IdType="pmc">PMC8642690</ArticleId><ArticleId IdType="pubmed">34766437</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna P., Fernanda P&#xe9;rez M., Castellar-Lopez J., Chang A., Montoya Y., Bustamante J., Rosales-Rada W., Mendoza-Torres E. Potential of angiotensin-(1-7) in COVID-19 treatment. Curr. Protein Pept. Sci. 2023;24:89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">36453502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Zang C., Xu Z., Zhang Y., Xu J., Bian J., Morozyuk D., Khullar D., Zhang Y., Nordvig A.S., et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat. Med. 2023;29:226&#x2013;235. doi: 10.1038/s41591-022-02116-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02116-3</ArticleId><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B., Sudry T., Flaks-Manov N., Yehezkelli Y., Kalkstein N., Akiva P., Ekka-Zohar A., David S.S., Lerner U., Bivas-Benita M., et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: Nationwide cohort study. BMJ. 2023;380:e072529. doi: 10.1136/bmj-2022-072529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinaro G., Gervais N., Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment&#x2014;An in vitro experimental approach. Stroke. 2002;33:1712&#x2013;1716. doi: 10.1161/01.STR.0000017284.77838.87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000017284.77838.87</ArticleId><ArticleId IdType="pubmed">12053016</ArticleId></ArticleIdList></Reference><Reference><Citation>Regoli D., Barabe J. Pharmacology of bradykinin and related kinins. Pharm. Rev. 1980;32:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">7015371</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber U., Engl C., Bayer M., K&#xf6;nig S. Neuropeptide reporter assay for serum, capillary blood and blood cards. MethodsX. 2020;7:100985. doi: 10.1016/j.mex.2020.100985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mex.2020.100985</ArticleId><ArticleId IdType="pmc">PMC7355720</ArticleId><ArticleId IdType="pubmed">32685383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>